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Abstract
Background: The post-translational modification of proteins, including glycosylation, differs between normal and 
tumor cells. The UDP-N-acetyl-D-galactosamine polypeptide N-acetylgalactosaminyltransferases (GalNAc-Tases) family 
of enzymes regulates the initial steps of mucin O-glycosylation and is responsible for the altered glycosylation state 
observed in cancer cells. Recently it was found that GalNAc-T14 mRNA is heterogeneously expressed in breast 
carcinomas compared to normal tissue, however the expression profile of GalNAc-T14 protein in breast carcinomas 
compared to normal tissue is still unknown. In this study, we assessed the expression profile of GalNAc-T14 protein in 
malignant and non-malignant breast tissues by immunohistochemistry to evaluate whether GalNAc-T14 might be a 
potential biomarker for breast cancer.
Methods: In formalin-fixed tissues, the expression level of GalNAc-T14 protein was evaluated by 
immunohistochemistry assay in breast tissues. Expression profiles were assessed in normal tissues, benign 
fibroadenomas and several types of carcinomas.
Results: Our results showed that GalNAc-T14 was heterogeneously expressed in breast carcinomas compared to non-
malignant tissue. GalNAc-T14 expression was observed in 47/56 (83.9%) carcinoma samples, 7/48 (14.6%) non-
malignant breast tissue samples. GalNAc-T14 expression level was associated with histological grade. For this enzyme a 
significant association with invasive ductal type, mucinous adenocarcinoma and ductal carcinoma in situ (DCIS) type 
was found.
Conclusion: Our results provide evidence that GalNAc-T14 may be a potential biomarker for breast cancer by 
immunohistochemistry. GalNAc-T14 expression level was associated with histological grade. GalNAc-T14 expression 
can provide new insights about breast cancer glycobiology.
Background
Polypeptide N-acetylgalactosaminyltransferase 14 (Gal-
NAc-T14, EC 2.4.1.41) belongs to a large subfamily of gly-
cosyltransferases residing in the Golgi apparatus. N-
acetylgalactosaminyltransferases (GalNAc-Tases) catal-
yse the first step in the O-glycosylation of mammalian
proteins by transferring N-acetyl-D-galactosamine (Gal-
NAc) to peptide substrates. Fifteen distinct members of
the mammalian GalNAc-Tases family have been identi-
fied and characterized [1-13]. Some of them are widely
distributed in various human tissues, but others show tis-
sue-specific distribution. The difference in tissue distri-
bution and substrate specificity toward peptides are
related to the diverse functions of these different sub-
types of GalNAc-Tases. Now it is known that the Gal-
NAc-Tase family is closely related to invasion, metastasis
and proliferation of many carcinomatous cells. It is widely
known that the O-glycosylation alters in malignant trans-
formation [14]. Tumor development is usually associated
to alterations in cellsurface carbohydrates. Glycosylation
changes arising as a consequence of malignant transfor-
m a t ion influe nc e c e ll  gr owt h as w e ll  as  diff e r e n tia t ion,
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adhesiveness and immunogenicity of cancer cells [15].
Tumor-associated carbohydrate antigens are produced
due to the deregulation of glycosyltransferases, resulting
in changes in enzyme activity and specificity for specific
substrates.
Altered expression of GalNAc-Tases could be one of the
mechanisms that explain the changes in mucin O-glyco-
sylation during malignant transformation [16]. Mucin
glycoproteins (mucins) expressed on carcinoma cells rep-
resenting a metastatic phenotype are qualitatively and
quantitatively different from those of the nonmetastatic
phenotype [17-19]. Alterations in the glycosylation of
carcinoma-associated mucins may modulate the biologi-
cal behavior of carcinoma cells and allow the cells to dis-
seminate, invade and survive at distant organ sites [20].
These alterations include aberrant glycosylation, and
incomplete glycosylation. The carbohydrate antigens on
the cell surface are useful for monitoring tumor status in
subjects with malignant diseases [21-24].
Variations of the GalNAc-Tases expression pattern have
been described in several cell carcinomas. Akita et al sug-
gested that GalNAc-T3 can serve as a new marker of non-
small cell lung cancers with specificity for histology and
prognosis [25]. Decreased expression of GalNAc-T1 and
increased expression of GalNAc-T2 and GalNAc-T3 have
b e e n  r e p o r t e d  i n  o r a l  s q u a m o u s  c e l l  c a r c i n o m a  w h e n
compared to the expression pattern in normal oral
mucosa [26]. Higher expression of GalNAc-T1, GalNAc-
T2 and GalNAc-T3 has also been described in colorectal
carcinoma when compared with the normal colonic epi-
thelium [27]. Different levels of expression of GalNAc-T3
were detected in patients with colorectal [12], lung [28],
pancreatic [29], gastric [30], gallbladder [31], prostate
[32] and extrahepatic bile duct carcinomas [33], and it
was identified as an independent factor of prognosis. Gal-
NAc-T6, which exhibits a high sequence homology to
GalNAc-T3, has been recently described to be expressed
i n  m o s t  d u c t a l  b r e a s t  c a r c i n o m a s  b u t  n o t  i n  n o r m a l
breast epithelium. This association is significant in the T1
tumor stage [34]. GalNAc-T3 and -T6 were also
described in association with breast malignant cell lines
[35]. GalNAc-T14 was first reported in 2003 by Wang et
al, who cloned its cDNA, designated it as GalNAc-T14
and confirmed that it is a new member of the GalNAc-
Tase family. Quantitative real-time polymerase chain
reaction (PCR) analysis revealed that the GalNAc-T14
transcript was highly expressed in kidney tissue, which
suggests that GalNAc-T14 might be involved in O-glyco-
sylation in the kidney [10]. Wagner et al found that
mRNA expression of the peptidyl O-glycosyltransferase
GalNAc-T14 correlated with Apo2L/TRAIL sensitivity in
pancreatic carcinoma, non-small-cell lung carcinoma and
melanoma cell lines, and up to 30% of samples from vari-
ous human malignancies including breast cancer, ovarian
cancer, lung cancer and skin cancer showed GalNAc-T14
overexpression using real-time PCR assays. RNA inter-
ference of GalNAc-T14 reduced cellular Apo2L/TRAIL
sensitivity, whereas overexpression increased responsive-
ness. These results uncover a new link between death-
receptor O-glycosylation and apoptotic signaling, provid-
ing potential predictive biomarkers for Apo2L/TRAIL-
based cancer therapy [36]. We have recently described
the mRNA expression of GalNAc-T14 in human breast
cancer cell lines and breast tumors. Immunohistochemi-
cal studies have shown an altered expression of some Gal-
NAc-Tases in malignant transformation. In the present
study we characterized the expression of GalNAc-T14 in
non-malignant and malignant breast tissues using immu-
nohistochemical assay. We demonstrated that GalNAc-
T14 was expressed in most breast carcinoma and there
were changes in its expression level during breast car-
cinogenesis. Expression of GalNAc-T14 was found to be
associated with clinicopathological characteristics of
breast carcinoma, therefore, GalNAc-T14 could be a spe-
cific biomarker for breast cancer.
Methods
Collection of tissue samples and histological classification
The study was performed using surgical specimens of
b r e a s t  c a r c i n o m a s  a n d  b r e a s t  a d e n o s i s  f r o m  p a t i e n t s
operated at No.3 Hospital (Baoding, China). The hospital
institutional ethical review committee approved this
study protocol, and all patients provided written
informed consent. Analysis of the expression of GalNAc-
T14 was performed in 104 breast tissue samples consti-
tuted by normal tissues (16), adenosis (32), invasive duc-
tal carcinomas (43), lobular carcinomas (4), ductal
carcinoma in situ (DCIS, 5) and mucinous adenocarci-
noma (4) fixed in 10% neutral formalin and embedded in
paraffin. Characteristics of breast cancer patients and
tumors are listed in Table 1. These normal tissues which
were more than 5 cm distant from carcinoma were from
the same invasive ductal carcinomas patients. Serial sec-
tions were cut and used for conventional histopathologic
diagnosis. Carcinomas were classified according to WHO
(2003). Age, presence of lymphatic invasion, nodal metas-
tasis and tumor localization were also recorded in every
case. The pathologic staging was achieved using the
WHO PTNM classification for breast carcinoma.
Immunohistochemistry
Immunohistochemical staining of GalNAc-T14 was per-
formed in 88 randomly chosen patients who had under-
gone surgical treatment for a breast disease at No.3
Hospital (Baoding, China) between 2008 and 2009 (56
patients with histopathological diagnosis of breast cancer
and 32 patients with non-malignant diseases). Elivision™
plus two-step system was used to detect GalNAc-T14Wu et al. BMC Cancer 2010, 10:123
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expression. Paraffin-embedded tissue was freshly cut (4
μm). The sections were dewaxed with xylene, and gradu-
ally hydrated in a decreasing ethanol series ending in dis-
tilled water. Endogenous peroxidase activity was
quenched using 0.3% hydrogen peroxide in methanol for
30 min and then washed in phosphate buffered saline
(PBS). Antigen retrieval was achieved using a pressure
boiler heating in retrieval solution, pH 6, at 125°C for 4
min, followed by a 20 min cooldown period at room tem-
perature. Sections were incubated with normal goat
serum diluted 1:5 in PBS containing 10% of BSA for 20
min. After that, sections were incubated overnight at 4°C
with the rabbit polyclonal antibody against the synthetic
peptide derived from residues 50-105 of human GalNAc-
T14 (Sigma) at the dilution of 1:15. After washing with
PBS, staining was performed by the Elivision™ plus two-
step system (Maixin Bio, China). Reactions were revealed
with 3,3'-diaminobenzidine (DAB, Sigma). Slides were
then counterstained with hematoxylin, washed, dehy-
drated with alcohol and xylene and mounted with cover-
slips. Between each step, sections were washed in PBS.
For every assay, omission of the primary antibody and
substitution by nonspecific immunoglobulin at the same
concentration was used as negative controls. For ER, PR,
and ErbB2 staining, sections were stained with the ER/
PR/ErbB2/P53 immunohistochemistry test kit (Zhong-
shan Co., Beijing, China), which includes the mouse
monoclonal antibodies against human ER, PR, ErbB2 and
P53 proteins.
Assessment of GalNAc-T14, ER, PR, ErbB2 and P53 
expression
GalNAc-T14 expression is diffuse or granular staining in
the cytoplasm. The immunostaining frequency for each
tumor was scored as follows: 0, for negative samples or,
10%stained tumor tissue; 1, for samples stained between
10 and 39% of tumor tissue; 2, for samples stained
between 40 and 79% of tumor tissue; and 3, for tumors
with 80% of stained tumor tissue. Signal intensity was
s c o r e d  a s  s t r o n g  ( 3 ,  d a r k  b r o w n  c o l o u r ) ,  m o d e r a t e  ( 2 ,
Table 1: Characteristics of patients and tumors
Median (range) n (%)
Age in years 51.8 (30-74)
Histological type
Invasive ductal 43 (76.80)
Invasive lobular 4 (7.15)
DCIS 5 (8.90)
Mucinous Adenocarcinoma 4 (7.15)
Nodal status
Negative 32
Positive 24
Histological grade
Grade 1 7
Grade 2 19
Grade 3 17
Estrogen receptors
Negative 27 (48.2)
Positive 29 (51.8)
Progesterone receptors
Negative 37 (66.1)
Positive 19 (33.9)
ErbB2
Negative 30 (53.5)
Positive 26 (46.5)
P53
Negative 6 (10.8)
Positive 50 (89.2)Wu et al. BMC Cancer 2010, 10:123
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medium brown colour), weak (1, light brown colour), and
nul (0, no immunostaining). Total immunostaining score
results from the multplication of both parameters. Sam-
ples were scored totally as follows: strong (+++, total
immunostaining score = 6~9), moderate (++, total immu-
nostaining scor = 3~4), weak (+, total immunostaining
score = 1~2), and null (-, total immunostaining score = 0).
Scores were established jointly by four observers under a
multi-head microscope. Clinicopathological information
was masked to the observers. ER, PR and P53 staining
was scored in a minimum of 300 histologically identified
neoplastic cells, showing nuclear reaction. Tumors with
positive ER, PR or P53 nuclear staining in >10% of tumor
cells were defined as ER, PR or P53 positive, respectively.
For ErbB2 protein, immunostainings were scored as
strong (2++ and 3+++), weak or negative (1+ and 0)
according to the rate of labelled tumor cells and the mem-
brane staining intensity.
Statistical Analysis
Statistical analysis was performed using standard statisti-
cal software SPSS version 13.0 (Chicago, Illinois). Corre-
lation between GalNAc-T14 expression and various
clinicopathological factors were analyzed using Fisher's
exact test. P < 0.05 was considered statistically significant.
Results
GalNAc-T14 expression was evaluated in 56 primary
tumors from breast cancer patients (43 ductal carcino-
mas, 4 lobular carcinomas, 5 DCIS and 4 mucinous ade-
nocarcinoma), 32 specimens from non-malignant breast
diseases, and 16 normal breast tissues. The results of the
immunohistochemical study of 104 breast tissues are
summarized in Table 2. The majority of breast cancers
were invasive ductal carcinoma. The breast carcinoma
cells showed perinuclear of diffuse cytoplasmic immu-
nostaining of GalNAc-T14 (Figure 1C-D). As illustrated
in Table 2, there was a significant correlation between the
expression of GalNAc-T14 and breast carcinomas. Gal-
NAc-T14 was expressed more obviously frequently in
cancers than in non-malignant tissues. GalNAc-T14
expression was observed in 47/56 (83.9%) carcinomas,
whereas only 7/48 (14.6%) showed GalNAc-T14 expres-
sion in non-maglinant tissues (P = 0.000) (Table 2). Gal-
NAc-T14 expression in different breast cancer types were
displayed in Figure 2. Invasive ductal carcinoma was
observed in 43/56 cancers, of which 37 (86.0%) were Gal-
NAc-T14 positive (8/37 showed a strong immunostain,
11/37 immunostained moderately, and 18/37 immunos-
tained weakly). Four invasive lobular carcinomas were
evaluated and three (75%) were GalNAc-T14 negative,
whereas one was immunostained weakly. The result is in
agreement with GalNAc-T14 expression revealed by real-
time quantitative PCR in several types of breast carcino-
mas tissues [36].
GalNAc-T14 expression was also evaluated in 5/5
(100%) adjacent ductal carcinoma in situ (DCIS) and 4/4
Table 2: Correlation of GalNAc-T14 expression with non-malignant tissues and carcinomas
Tissue type Total number Cytoplasm GalNAc-T14 expression * P value
Positive (%) Negative (%)
non-malignant 48 7 (14.6%) 41 (85.4%) 0.000
carcinomas 56 47 (83.9%) 9 (16.1%)
* The positive cytoplasmic immunohistochemical reactivity of GalNAc-T14 in breast carcinomas includes strong, moderate and weak staining.
Figure 1 Immunohistochemical evaluation of GalNAc-T14 in 
breast carcinomas and normal tissue. A, Adenosis. B, Normal. C, Can-
cer. D, Cancer and surrounding normal tissue. E, Nonspecific immuno-
globulin was used as a negative control. Magnification: A, B, C, E ×400; 
D ×100. (In order to show the immunostaining profile of carcinomas 
and normal tissue surrounding carcinomas in the same microscopic 
field, 100× magnification was used)Wu et al. BMC Cancer 2010, 10:123
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(100%) mucinous adenocarcinoma. Of the 5 DCIS, 4
(80%) were immunostained strongly and 1 (20%) was
immunostained moderately. Three of four mucinous ade-
nocarcinomas were immunostained strongly and one was
immunostained weakly. In contrast to the positive
expression frequently observed in breast cancers, Gal-
NAc-T14 was rarely detected in non-malignant breast
diseases. Only 7/48 (14.6%) of non-malignant tissues
showed GalNAc-T14 expression, distributed as follows:
5/32 adenosis, 2/16 normal breast tissues. In order to
detect the difference of GalNAc-T14 expression between
normal tissues and benign tissues, 32 specimens from
non-malignant breast diseases and 16 normal breast tis-
sues that were from the cancer patients were analyzed.
No difference was observed between them (Figure 1A-B).
As showed in Figure 1D, GalNAc-T14 has a strong cyto-
plasmic immunostaining in carcinomas and no cytoplas-
mic immunostaining was observed in normal tissue
surrounding carcinomas. No staining was observed with
nonspecific immunoglobulin as a negative control (Figure
1E).
We observed a statistically significant association
between GalNAc-T14 expression and tumor grading in
invasive ductal carcinomas. High expression of GalNAc-
T14 was found frequently in G1 tumors than G2 and G3
tumors. The relationship between GalNAc-T14 expres-
sion and clinicopathological factors is shown in Table 3.
The cases with higher histological grade showed lower
level of GalNAc-T14 expression (Figure 3). The expres-
sion level of GalNAc-T14 was high in 6/7 (85.7%) of G1
tumors, moderate in 9/19 (47.4%) of G2 tumors, and low
(14/17, 82.4%) or null (2/17, 11.8%) in G3 tumors (p <
0.05). No correlation was found between GalNAc-T14
expression and ER, PR, ErbB2 protein levels. The relative
expression level of GalNAc-T14 was not correlated with
the expression of P53.
In immunocytochemical studies, GalNAc-T14 anti-
body was reactive with MCF-7 breast cancer cell lines
(data not shown). The result was in agreement with Gal-
NAc-T14 expression revealed by semi-quantitative RT-
PCR in the cells lines (unpublished data).
Discussion
Abnormal O-glycans expressed by cancer cells have func-
tional importance in cell adhesion, invasion, and metasta-
sis [15]. Alterations in mucin-type O-glycans has been
associated with malignant transformation, resulting in
the formation of less complex structures and leading to
an increase of the simple short determinants. Protein O-
glycosylation is deregulated in breast cancer cells, leading
to the accumulation of simple mucin-type tumor-associ-
ated antigens [37]. The expression of GalNAc-T14 mRNA
was analyzed in normal and malignant tissue from breast,
skin, lung, pancreas, ovary, endometrium, bladder and
lymphoid cancers. A subset of tumor samples, ranging
from 10% in lobular breast cancer to 30% in lung cancer
and diffuse large B-cell lymphoma, showed GalNAc-T14
mRNA overexpression [36]. Under thees circumstances,
we hypothesize the expression of GalNAc-T14 may be a
useful biomarker for breast cancer by immunohis-
tochemistry.
It has been shown that several glycosyltransferases are
useful tumor markers. Owing to the later discovery of
this enzyme, GalNAc-T14 was rarely studied. Up to now,
the expression of GalNAc-T14 protein in breast cancer
has not been reported. In the present work we used a
polyclonal antibody against this enzyme, to evaluate the
potential role of GalNAc-T14 as a breast cancer bio-
marker. In the immunohistochemical study presented
here, we described for the first time the expression of
GalNAc-T14 protein in breast cancer. Our results showed
that GalNAc-T14 is expressed in only 7/48 samples
(14.6%) of non-malignant breast tissue, whereas it is
expressed in most breast carcinomas (47/56, 83.9%).
These results are in agreement with recent mRNA data
that were obtained from non-malignant and malignant
breast tissues using semi-quantitive RT-PCR in our labo-
ratory (data not shown). It was found that the expression
of GalNAc-T14 in breast invasive ductal carcinomas was
associated with histological grading. Higher histological
grading corresponded to lower expression level of Gal-
NAc-T14.
E x p r e s s i o n  l e v e l s  f o r  G a l N A c - T 1 4  m R N A  h a v e  b e e n
detected in human normal tissue and tumor tissue sam-
ples, including skin, pancreas, lung, breast, ovary, endo-
metrium, bladder and lymph. Expression of the mRNA
transcript which encodes the O-glycosylation initiating
enzyme GalNAc-T14, was markedly higher in carcinoma
tissue of lung, breast, ovary, endometrium, bladder versus
normal tissue of those [36]. The members of the GalNAc-
Tases family, GalNAc-T1, -T2, -T3, -T4 and -T6 were
Figure 2 GalNAc-T14 expression in different breast cancer type. 
A, Invasive ductal carcinoma. B, Invasive lobular carcinoma. C, DCIS. D, 
Mucinous Adenocarcinoma. Magnification: ×400.Wu et al. BMC Cancer 2010, 10:123
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d e t e c t e d  i n  a  r a n g e  o f  b r e a s t  c e l l  l i n e s  b y  i m m u n o cy -
tochemistry with confocal scanning laser microscopy.
The cells were chosen to represent a range of phenotypes
from 'normal'/benign (HMT 3522), primary, non-meta-
static breast cancer (BT 474), to aggressive, metastatic
breast cancer (ZR75-1, T47D, MCF-7, DU 4,475). Gal-
NAc-T1 and -T2 were detectable at low levels in all cell
lines studied. GalNAc-T4, which has never been
described in breast, was very weakly detectable in BT
474, MCF-7 and T47D. GalNAc-T3 and -T6 were weakly
detectable or undetectable, respectively, in the cell line
HMT 3522 derived from normal/benign breast epithe-
lium, but were readily detectable in all malignant cell
lines. Thus, a broader range of GalNAc-Tases were
detectable in the malignant cell lines in comparison to the
'normal'/benign cells, where only the housekeeping Gal-
NAc-T1 and -T2 were present. Expression of normally
tightly restricted GalNAc-Tases may result in initiation of
O-linked glycosylation at normally unoccupied potential
glycosylation sites leading to altered glycoforms of pro-
teins with changed biological activity which may contrib-
ute to the pathogenesis of cancer [35]. Different levels of
GalNAc-T2 have also been detected in oral squamous cell
carcinoma and colorectal carcinoma, and this has been
associated with a poor prognosis. GalNAc-T14 exhibits a
high amino acid sequence homology to GalNAc-T2, but
in vitro studies have indicated that the most preferred
glycosylation site within Muc5AC by GalNAc-T14 was
different from the site preferred by GalNAc-T2. So the
catalytic profiles of GalNAc-T14 may be different from
that of GalNAc-T2. Our results suggest that GalNAc-T14
also may play a role in the biological characteristics of
breast carcinoma cells, most probably through the varia-
tion in mucin O-glycosylation. We hypothesize that inva-
sive ductal carcinoma with high histological grading
would likely result in invasion and metastasis due to the
downregulation of GalNAc-T14 expression. This
occurence induces an incomplete elongation of O-glycan
Table 3: Relationship between GalNAc-T14 expression and clinicopathological factors
Histopathological 
diagnosis
Grade Sample 
number
GalNAc-T14 staining
Low Moderate Strong
Invasive ductal carcinoma 1 6 +++
11 + +
2 2 +++
29 + +
24+
240
31 + +
31 4+
320
Mucinous Adenocarcinoma 3 +++
1+
Invasive lobular carcinoma 3 0
1+
DCIS 1 ++
4 +++
Normal beast tissue 14 0
2+
Adenosis 27 0
4+
1+ +Wu et al. BMC Cancer 2010, 10:123
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saccharide chains in mucins that can lead to the expres-
sion of shorter carbohydrate structures, such as the TF,
sialyl-Tn, or Tn antigens. Tn antigen determinant (Gal-
NAc-O-Ser/Thr: the innermost O-linked structure),
which is usually masked by additional sugar residues in
normal tissues, was characterized as one of the most spe-
cific human cancer-associated structures, and it was
detected in approximately 90% of human carcinomas [38]
A direct correlation has been shown between carcinoma
aggressiveness and the density of expression of Tn in the
tumor [39]. Thus, expression of the Tn determinant could
be the result of glycosyltransferases deregulation via
changes in enzyme activity and/or in substrate specificity
[40]. The other possible reason is that both O-glycosyla-
tion and phosphorylation take place on the same catalyti-
cal sites on Ser/Thr residues. Therefore, O-glycosylation
may competitively inhibit the Ser/Thr phosphorylation.
Abnormal expression of GalNAc-T14 may result in initia-
tion of O-linked glycosylation at normally unoccupied
potential phosphorylation sites leading to altered pro-
teins with changed biological activity which may contrib-
ute to the pathogenesis of cancer.
Conclusions
In summary, our result is in line with previous studies
showing that breast carcinoma tissue GalNAc-T14
mRNA was expressed heterogeneously in breast cancer.
The abnormal expression of GalNAc-T14 in breast carci-
nomas may have induced changes in cellular functions
including adhesion and invasion. Our results provide evi-
dence that GalNAc-T14 may be a potential biomarker for
breast cancer by immunohistochemistry. Moreover, the
expression levels of GalNAc-T14 were associated with
histological grade in breast invasive ductal carcinoma and
tumour progression. For this enzyme a significant associ-
ation with invasive ductal type, mucinous adenocarci-
noma and DCIS type was found. Considering that
abnormal O-glycosylation greatly contributes to the phe-
notype and biology of breast cancer cells, our results con-
tribute to understanding the molecular mechanisms that
underlie aberrant glycosylation in breast carcinogenesis
and in breast carcinoma. To extend our observations, a
follow-up study of a larger number of cases is necessary
to determine the potential clinical value of this marker.
Further studies are also required to determine the biolog-
ical role of GalNAc-T14 in breast tumor development,
growth, invasion and metastasis.
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breast carcinomas with different histological grades. A, the cases 
with histological grade 1. B, the cases with histological grade 2. C, the 
cases with histological grade 3.Wu et al. BMC Cancer 2010, 10:123
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